Sheet <u>1</u> of <u>1</u>

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 14875-134US1

Application No. 10/510,971

Information Disclosure Statement by Applicant (Use several sheets if necessary) Applicant Tetsuo Kojima

Filing Date
October 12, 2004

Group Art Unit

(37 CFR §1.98(b))

			U.S. Pate	nt Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	,,,					

	Foreign Patent Documents or Published Foreign Patent Applications						
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No.
	AB						
•	AC						

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner	Desig.						
Initial	ID	Document					
	AD	McGuinness BT et al., "Phage diabody repertoires for selection of large number of bispecific					
		antibody fragments", Nature Biotechnology, Vol. 14(9), pages 1149-1154 (1996).					
		DeNardo D.G. et al., "Anti-HLA-DR/anti-DOTA diabody construction in modular gene design					
	AE	platform: bispecific antibodies for pretargeted radioimmunotherapy", Cancer Biotherapy &					
		Radiopharmaceuticals, Vol. 16(6), pages 525-535 (2001).					
	AF	Andris-Widhopf J. et al., "Methods for the generation of chicken monoclonal antibody fragments by					
	Ar	phage display", Journal of Immunological Methods, Vol. 242, pages 159-181 (2000).					
		Turner D.J. et al., "Importance of the linker in expression of single-chain Fv antibody fragments:					
<u> </u>	AG	optimization of peptide sequence using phage display technology", Journal of Immunological					
		Methods, Vol. 205, pages 43-54 (1997).					
,	AH	Tang Y. et al., "Selection of linkers for a catalytic single-chain antibody using phage display					
	741	technology", The Journal of Biological Chemistry, Vol. 271(26), pages 15682-15686 (1996).					
بنيو	AI -	Holliger P. et al., "'Diabodies', small bivalent and bispecific antibody fragments", Proc. Natl. Acad.					
	AI .	Sci. USA, Vol. 90, pages 6444-6448 (1993).					

Examiner Signature /Lynn Bristol/	Date Considered 07/31/2007
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	of in conformance and not considered. Include copy of this form with

Sheet	1	C	1
Sheet		of	
		O.	ı.

Substitute (Modified)

SER (37 CER) S

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office

Attorney's Docket No. 14875-148US1 Application No. N/A

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

Applicant Tetsuo Kojima

July 20, 2005

Filing Date

Group Art Unit

§1.98(b)

U.S. Patent Documents

Examiner | Desig. | Document | Publication | ID | Number | Date | Patentee | Class | Subclass | If Appropriate | AA | | Publication | Patentee | Class | Subclass | If Appropriate | Class | Cl

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AB							

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner	Desig.						
Initial	ID	Document					
	AC	McGuinness BT et al., "Phage diabody repertoires for selection of large number of bispecific					
	- 46	antibody fragments", Nature Biotechnology, Vol. 14(9), pages 1149-1154 (1996).					
		DeNardo D.G. et al., "Anti-HLA-DR/anti-DOTA diabody construction in modular gene design					
<u> </u>	AD	platform: bispecific antibodies for pretargeted radioimmunotherapy", Cancer Biotherapy &					
· ·		Radiopharmaceuticals, Vol. 16(6), pages 525-535 (2001).					
	AF	Andris-Widhopf J. et al., "Methods for the generation of chicken monoclonal antibody fragments by					
	AL-	phage display", Journal of Immunological Methods, Vol. 242, pages 159-181 (2000).					
_		Turner D.J. et al., "Importance of the linker in expression of single-chain Fv antibody fragments:					
-	AF	oprimization of peptide sequence using phage display technology", Journal of Immunological					
		Methods, Vol. 205, pages 43-54 (1997).					
	AG	Tang Y. et al., "Selection of linkers for a catalytic single-chain antibody using phage display					
	Λ0	technology", The Journal of Biological Chemistry", Vol. 271(26), pages 15682-15686 (1996).					
	AII	Holliger P. et al., "Diabodies", small bivalent and bispecific antibody fragments", Proc. Natl. Acad.					
	AII	Sci. USA, Vol. 90, pages 6444-6448 (1993).					

Examiner Signature /Lynn Bristol/	Date Considered 07/31/2007
EXAMINER: Initials citation considered. Draw line through citation if no	it in conformance and not considered. Include copy of this form with

next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. Application No. 14875-134US1 10/510,971		
	closure Statement	Applicant Tetsuo Kojima		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date October 12, 2004	Group Art Unit	

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

	Foreig	n Patent Docu	ments or P	ublished Foreign	Patent	Applicati	ons	
Examiner	Desig.	Document	Publication	Country or			Transl	ation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
LAB	AB	CA 2 331 641	11/11/1999	Canada				
	AC	EP 0 774 511	05/21/1997	EPO				
	AD	DE 198 19 846	11/11/1999	Germany			see AB	
	AE	JP 2001-523971	11/27/2001	Japan	·		see AG	
	AF	WO 96/34892	11/07/1996	WIPO				
	AG	WO 98/50431	11/12/1998	WIPO				
	AH	WO 00/44788	08/03/2000	WIPO				
	AI	WO 01/44282	06/21/2001	WIPO				
	AJ	WO 01/70775	09/27/2001	WIPO				
	AK	WO 03/087163	10/23/2003	WIPO.			х	

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner	Desig.					
Initial	ID	Document				
AL Carter, "Bispecific human IgG by design," J. Immunol. Methods, 248:7-15		Carter, "Bispecific human IgG by design," J. Immunol. Methods, 248:7-15 (2001)				
	AM De Jonge et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments, Mol. Immunol., 32:1405-1412 (1995)					
	ΑŅ	Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," Nucleic Acids Res., 19:4133-4137 (1991)				
	AO	Hudson et al., "High avidity scFv multimers; diabodies and triabodies," J. Immunol. Methods, 231:177-189 (1999)				
	AP	Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies," J. Mol. Biol., 330:99-111 (2003)				
	AQ	Krebber et al., "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," J. Immunol. Methods, 201:35-55 (1997)				
	AR	Kurucz et al., "Retargeting of CTL by an Efficiently Refolded Bispecific Single-Chain Fv Dimer Produced in Bacteria," J. Immunol., 154:4576-4582 (1995)				
J	AS	Little et al. "Of mice and men: hybridoma and recombinant antihodies." Immunol. Today				

Examiner Signature	/Lynn Bristol/	Date Considered	07/31/2007
EXAMINER: Initials citation next communication to app	on considered. Draw line through citation if no olicant.	t in conformance and not con	sidered. Include copy of this form with

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. Application No. 14875-134US1 10/510,971		
	closure Statement	Applicant Tetsuo Kojima		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date October 12, 2004	Group Art Unit	

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
LAB AT		Merchant et al., "An efficient route to human bispecific IgG," Nat. Biotechnol., 16:677-681 (1998)			
	AU	Peipp et al., "Bispecific antibodies targeting cancer cells," Biochem. Soc. Trans., 30:507-511 (2002)			
	AV Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997)				
	Ridgway et al., "Knobs-into-holes' engineering of antibody C _H 3 domains for heavy chain heterodimerization," <i>Protein Eng.</i> , 9:617-621 (1996)				
	·AX	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)			
	AY	Skerra, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli," Gene, 151:131-135 (1994)			
	AZ	Völkel et al., "Optimized linker sequences for the expression of monomeric and dimeric bispecifi single-chain diabodies," <i>Protein Eng.</i> , 14:815-823 (2001)			
V	AAA Zuo et al., "An efficient route to the production of an IgG-like bispecific antibody," Protein En				
	AAR	Supplemental RPER (4/17/06)			

Examiner Signature Date Considered 07/31/2007 /Lynn Bristol/ EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	1	of	1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-134US1	Application No. 10/510,971	
	ion Disclosure Statement	Applicant Tetsuo Kojima		
(Use several sh	eets if necessary)	Filing Date	Group Art Unit	
(37 CFR §1.98(b))	·	June 21, 2005	1646	

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
LAB	AA	2004/0219643	11/04/2004	Winter et al.			
1	AB	2006/0159673	07/20/2006	Kojima			
V	AC	2006/0269989	11/30/2006	Miyazaki et al.			

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass		lation
Hilliai		Number	Date	Patent Office	Class	Subciass	Yes	No
	AD				Ī			

. (Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.			
Initial	ID	Document		
220	AE	Goldstein et al., "Cytolytic and Cytostatic Properties of an Anti-Human FcγRI (CD64) × Epidermal Growth Factor Bispecific Fusion Protein," J. Immunol., 158:872-879 (1997)		

Examiner Signature Date Considered /Lynn Bristol/ 07/31/2007